个人简介
牟相宇，现任中山大学医学院副教授，博士生导师。主要从事人体病原菌和人体微生物群的相关研究，研究成果发表在PNAS, eBioMedicine, Microbiome, Protein & Cell, Gut Microbes等学术期刊上。
学术经历
2004-2008，华中农业大学，生物工程专业，学士
2008-2013，罗德岛大学，细胞与分子生物学专业，博士
2013-2018，哈佛医学院/麻省总医院，博士后
2018至今，中山大学医学院，副教授
研究兴趣
1. 人体病原菌的致病机理与防治策略——通过细菌遗传学等手段研究细菌分泌系统、毒素等毒力因子在病原菌致病过程中的分子机理，并通过抗毒力剂、疫苗等手段实现对病原菌感染的干预。
2. 人体共生细菌的在疾病中的作用与利用——针对人体微生物群中与疾病相关的菌种进行分离培养，在动物模型中识别对疾病具有促进或预防的菌种，利用细菌遗传学等手段解析其分子机制，为疾病的防控提供新的干预策略。
研究生招生学科
生物学（071000）；生物与医药（专业学位，086000）
招聘信息
本课题组长期招收博士后，我们将提供有竞争力的薪酬待遇与职业发展环境。
代表性著作
1. Xu, J., Li, P., Li, Z., Liu, S., Guo, H., Lesser, C. F., Ke, J., Zhao, W.#, & Mou, X. # (2024). Gut bacterial type III secretion systems aggravate colitis in mice and serve as biomarkers of Crohn's disease. EBioMedicine, 107, 105296. https://doi.org/10.1016/j.ebiom.2024.105296.
2. Chou, S., Guo, H., Zingl, F. G., Zhang, S., Toska, J., Xu, B., Chen, Y., Chen, P., Waldor, M. K., Zhao, W. #, Mekalanos, J. J. #, & Mou, X. # (2023). Synthetic peptides that form nanostructured micelles have potent antibiotic and antibiofilm activity against polymicrobial infections. Proceedings of the National Academy of Sciences of the United States of America, 120(4), e2219679120.
3. Liu, S., Men, X., Guo, Y., Cai, W., Wu, R., Gao, R., Zhong, W., Guo, H., Ruan, H., Chou, S., Mai, J., Ping, S., Jiang, C., Zhou, H., Mou, X. #, Zhao, W. #, & Lu, Z. # (2023). Gut microbes exacerbate systemic inflammation and behavior disorders in neurologic disease CADASIL. Microbiome, 11(1), 202.
4. Mao, Y., Li, Y., Xiao, X., Mai, J., Lin, G., Liu, S., Huang, J., Zhou, X., Mou, X. #, & Zhao, W. # (2025). Oncomicrobial vaccines mitigate tumor progression via precisely targeting oncomicrobes in mice. Protein & cell, pwae067.
5. Chen, S., Zhang, Z., Liu, S., Chen, T., Lu, Z., Zhao, W., Mou, X. #, & Liu, S. # (2024). Consistent signatures in the human gut microbiome of longevous populations. Gut microbes, 16(1), 2393756.
6. Huang, J., Liu, S., Li, P., Wei, L., Lin, G., Lin, J., Luo, Y., Liu, Y., Mao, Y., Ruan, H., Qin, B., Fan, P., Lu, T., Cai, W., Yi, H., Mou, X. #, Lu, Z. #, Zhao, W. #, & Wu, A. # (2024). Multi-omics analysis of gut-brain axis reveals novel microbial and neurotransmitter signatures in patients with arteriosclerotic cerebral small vessel disease. Pharmacological research, 208, 107385.
7. Mao, Y., Xiao, X., Zhang, J., Mou, X. #, & Zhao, W. # (2023). Designing a multi-epitope vaccine against Peptostreptococcus anaerobius based on an immunoinformatics approach. Synthetic and systems biotechnology, 8(4), 757–770.
8. Zhang, J., Chen, X., Zou, J., Li, C., Kang, W., Guo, Y., Liu, S., Zhao, W., Mou, X. #, Huang, J. #, & Ke, J. # (2022). MADET: a Manually Curated Knowledge Base for Microbiomic Effects on Efficacy and Toxicity of Anticancer Treatments. Microbiology spectrum, 10(6), e0211622.
9. Liu, S., Zhao, W., Lan, P. #, & Mou, X. # (2021). The microbiome in inflammatory bowel diseases: from pathogenesis to therapy. Protein & cell, 12(5), 331–345.
10. Huang, J., Liu, W., Kang, W., He, Y., Yang, R., Mou, X. #, & Zhao, W. # (2022). Effects of microbiota on anticancer drugs: Current knowledge and potential applications. EBioMedicine, 83, 104197.
11. Chou, S., Zhang, S., Guo, H., Chang, Y. F., Zhao, W. #, & Mou, X. # (2022). Targeted Antimicrobial Agents as Potential Tools for Modulating the Gut Microbiome. Frontiers in microbiology, 13, 879207.
12. Jiang, Q., Li, T., Chen, W., Huo, Y., Mou, X. #, & Zhao, W. # (2022). Microbial regulation of offspring diseases mediated by maternal-associated microbial metabolites. Frontiers in microbiology, 13, 955297.
13. Mou, X., Souter, S., Du, J., Reeves, A. Z., & Lesser, C. F. # (2018). Synthetic bottom-up approach reveals the complex interplay of Shigella effectors in regulation of epithelial cell death. Proceedings of the National Academy of Sciences of the United States of America, 115(25), 6452–6457.
#通讯作者
